title: MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Michael W M
authors.initials: MW
authors.lastname: Kühn
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Hadler
authors.affiliation: Epizyme, Inc., Cambridge, MA, USA.
authors.forename: Scott R
authors.initials: SR
authors.lastname: Daigle
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Richard P
authors.initials: RP
authors.lastname: Koche
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
authors.forename: Andrei V
authors.initials: AV
authors.lastname: Krivtsov
authors.affiliation: Epizyme, Inc., Cambridge, MA, USA.
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Olhava
authors.affiliation: The Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Caligiuri
authors.affiliation: Divisions of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
authors.forename: Gang
authors.initials: G
authors.lastname: Huang
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
authors.forename: James E
authors.initials: JE
authors.lastname: Bradner
authors.affiliation: Epizyme, Inc., Cambridge, MA, USA.
authors.forename: Roy M
authors.initials: RM
authors.lastname: Pollock
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA armstros@mskcc.org.
authors.forename: Scott A
authors.initials: SA
authors.lastname: Armstrong
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D020440:Gene Duplication; D011495:Histone-Lysine N-Methyltransferase; D006657:Histones / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008780:Methyltransferases / Q000037:antagonists & inhibitors*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D020080:Tandem Repeat Sequences
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006657:Histones; D051788:Myeloid-Lymphoid Leukemia Protein; C473477:DOT1L protein, human; D008780:Methyltransferases; D011495:Histone-Lysine N-Methyltransferase
keywords: DOT1L inhibition; MLL-PTD; leukemia